New guidelines recommend evaluation of osteoporosis risk for
- Guidelines developed by the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology and published in the journal Endocrine Practice

- The guidelines recommend that all postmenopausal women aged 50 and older be evaluated for osteoporosis risk. Such evaluation should include a detailed history, physical exam and clinical fracture risk assessment

- Strongly recommend medications for patients with osteopenia or low bone mass and a history of a fragility fracture of the hip or spine. Medications that reduce the risk of fractures include alendronate, risedronate, zoledronic acid and denosumab

- Treatment with teriparatide should be limited to two years

- For patients with moderate fracture risk, the guidelines recommend that stable patients take a "drug holiday" after taking an oral bisphosphonate for five years or an intravenous bisphosphonate for three years...
Dr. V●●●●●●i L. and 8 others like this1 share